ILMN
57
-3
BAX
47
3
CA
4
-10
FAST
60
-4
AAP
27
-8
WEC
46
-5
FIS
51
-4
PVH
53
-2
VRSK
56
-3
DHI
58
-3
CLX
56
-2
NWSA
62
-5
HBAN
59
3
SHW
52
-9
MMM
38
-6
DOW
40
-2
AVY
48
-3
R
57
-2
COF
57
-2
WY
39
-3
ILMN
57
-3
BAX
47
3
CA
4
-10
FAST
60
-4
AAP
27
-8
WEC
46
-5
FIS
51
-4
PVH
53
-2
VRSK
56
-3
DHI
58
-3
CLX
56
-2
NWSA
62
-5
HBAN
59
3
SHW
52
-9
MMM
38
-6
DOW
40
-2
AVY
48
-3
R
57
-2
COF
57
-2
WY
39
-3
Financhill
Back

Stoke Therapeutics 10K Form

Sell
37

STOK
Stoke Therapeutics

Last Price:
12.03
Seasonality Move:
14.1%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive STOK News And Ratings

See the #1 stock for the next 7 days that we like better than STOK

STOK Financial Statistics

Sales & Book Value

Annual Sales: $8.78M
Cash Flow: $-17.52M
Price / Cash Flow: 0
Annual Sales: $4.64
Price / Book: 2.72

Profitability

EPS (TTM): -2.18000
Net Income (TTM): $-103.57M
Gross Margin: --
Return on Equity: -57.17%
Return on Assets: -41.83%

Stoke Therapeutics Earnings Forecast

Key Stoke Therapeutics Financial Ratios

  • The Research & Development expenses have been 936.57% of Revenue.
  • The Net Earning history of STOK is -1,192.47% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 2 years.

Stoke Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: STOK
CUSIP: 86150R
Website: stoketherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.67
Quick Ratio: 6.34

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

STOK Technical Analysis vs Fundamental Analysis

Sell
37
Stoke Therapeutics (STOK) is a Sell

Is Stoke Therapeutics a Buy or a Sell?